Pharmacoeconomic Review Report
Pharmacoeconomic Review Report. Drug. Sofosbuvir (Sovaldi) (400 mg/tablet) Indication. Sofosbuvir is indicated for the treatment of chronic hepatitis C virus (CHC) infection in adult patients with compensated liver disease, including cirrhosis, as follows: For the treatment of genotype 1 and genotype 4 CHC infection in combination with ...